This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The Molecular Pathology Core provides state-of-the-art instrumentation and support personnel for the research efforts of the Department of Pathology staff, members of the COBRE Center for Cancer Research Development, and academic community. Fee-based services include Laser Capture Microdissection, Quantitative Real-Time PCR, Tissue Microarray production, tissue banking, automated immunohistochemical staining, data and image analysis. Our 1300 sq. ft. facility is located in the Aldrich Building at Rhode Island Hospital. Over 32 research groups have made use of our services and facilities. Availability: Investigators are required to complete a detailed tissue request form obtainable through our website at:www.lifespan.org/rih/services/cobre. IRB project approval is required. Cost: Refer to website for fee list: www.lifespan.org/rih/services/cobre BioAnalyzer QC Major Equipment Arturus Autopix Laser Capture Microdissection System Ventana Discovery System Agilent Bioanalyzer Stratagene Multiplex PCR System Microscope Imaging System Leica Cryostat Tissue Microarrayer Revco Freezers (2) Microtome

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR017695-08
Application #
8359712
Study Section
Special Emphasis Panel (ZRR1-RI-B (01))
Project Start
2011-05-01
Project End
2012-04-30
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
8
Fiscal Year
2011
Total Cost
$373,377
Indirect Cost
Name
Rhode Island Hospital
Department
Type
DUNS #
075710996
City
Providence
State
RI
Country
United States
Zip Code
02903
Šrajer Gajdošik, Martina; Hixson, Douglas C; Brilliant, Kate E et al. (2018) Soft agar-based selection of spontaneously transformed rat prostate epithelial cells with highly tumorigenic characteristics. Exp Mol Pathol 105:89-97
Lopez, Chelsea E; Sheehan, Hannah C; Vierra, David A et al. (2017) Proteomic responses to elevated ocean temperature in ovaries of the ascidian Ciona intestinalis. Biol Open 6:943-955
Francois-Vaughan, Heather; Adebayo, Adeola O; Brilliant, Kate E et al. (2016) Persistent effect of mTOR inhibition on preneoplastic foci progression and gene expression in a rat model of hepatocellular carcinoma. Carcinogenesis 37:408-419
Li, Ming; Tucker, Lynne D; Asara, John M et al. (2016) Stem-loop binding protein is a multifaceted cellular regulator of HIV-1 replication. J Clin Invest 126:3117-29
Breen, Lucas D; Pu?i?-Bakovi?, Maja; Vu?kovi?, Frano et al. (2016) IgG and IgM glycosylation patterns in patients undergoing image-guided tumor ablation. Biochim Biophys Acta 1860:1786-94
Mulvey, Hillary E; Chang, Audrey; Adler, Jason et al. (2015) Extracellular vesicle-mediated phenotype switching in malignant and non-malignant colon cells. BMC Cancer 15:571
Cheng, Yan; Holloway, Michael P; Nguyen, Kevin et al. (2014) XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther 13:675-86
Yousuf, Saad; Duan, MeiLi; Moen, Erika L et al. (2014) Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer. PLoS One 9:e92478
Panagopoulos, Kiriaki; Cross-Knorr, Sam; Dillard, Christen et al. (2013) Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure. Mol Cancer 12:118
Perez, K; Walsh, R; Brilliant, K et al. (2013) Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. Exp Mol Pathol 95:74-82

Showing the most recent 10 out of 127 publications